Described herein, inter alia, are IGF2BP2 inhibitor compounds and methods of using the same.

Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

An additive for rubber that enables a rubber composition to have excellent low heat generating property and processability, a rubber composition containing the additive for rubber, and a tire using the same are provided. A rubber composition comprises a hydrazone compound represented by the following Formula (I): ##STR00001##
where R.sup.1 and R.sup.2 each independently represent a hydrogen atom, an alkyl group with a carbon number of 1 to 16, or an alkenyl group with a carbon number of 2 to 6, and A represents a group represented by the following Formula (A-1) or Formula (A-2): ##STR00002##

An additive for rubber that enables a rubber composition to have excellent low heat generating property and processability, a rubber composition containing the additive for rubber, and a tire using the same are provided. A rubber composition comprises a hydrazone compound represented by the following Formula (I): ##STR00001##
where R.sup.1 and R.sup.2 each independently represent a hydrogen atom, an alkyl group with a carbon number of 1 to 16, or an alkenyl group with a carbon number of 2 to 6, and A represents a group represented by the following Formula (A-1) or Formula (A-2): ##STR00002##